ALRN insider filings

Aileron Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-12-09. Screen ALRN transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for ALRN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Aileron Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2024-12-094WINDSOR JAMES BRIAN — President and CEOPurchase (P): 239 @ $2.24 · Purchase (P): 161 @ $2.25EDGAR
2024-12-064Aivado Manuel — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2024-12-064Ambros Reinhard J. — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2024-12-064Fairey William — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2024-12-064Musso Alan A — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2024-12-064VON RICKENBACH JOSEF H — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2024-12-044WINDSOR JAMES BRIAN — President and CEOGrant/award (A): 517,500 (derivative) @ $0EDGAR
2024-08-224Aivado Manuel — DirectorGrant/award (A): 2,725 (derivative) @ $0EDGAR
2024-08-224Fairey William — DirectorGrant/award (A): 2,725 (derivative) @ $0EDGAR
2024-08-224Ambros Reinhard J. — DirectorGrant/award (A): 2,725 (derivative) @ $0EDGAR
2024-08-224Musso Alan A — DirectorGrant/award (A): 2,725 (derivative) @ $0EDGAR
2024-08-224VON RICKENBACH JOSEF H — DirectorGrant/award (A): 2,725 (derivative) @ $0EDGAR
2024-06-174UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO — 10% ownerSale (S): 1,900 @ $3.30 · Sale (S): 4,707 @ $3.25EDGAR
2024-06-124UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO — 10% ownerSale (S): 9,577 @ $3.30 · Sale (S): 5,250 @ $3.25 · Sale (S): 502 @ $3.35 · Sale (S): 9,341 @ $3.25 · Sale (S): 1 @ $3.27EDGAR
2024-06-074UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO — 10% ownerSale (S): 6,291 @ $3.30 · Sale (S): 1,100 @ $3.27 · Sale (S): 3,184 @ $3.30 · Sale (S): 1,564 @ $3.25 · Sale (S): 176 @ $3.30EDGAR
2024-05-144/AUNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO — 10% ownerSale (S): 3,100 @ $4.10 · Sale (S): 100 @ $4.11 · Sale (S): 1,750 @ $4.12 · Sale (S): 380 @ $4.13 · Sale (S): 1,600 @ $4.14 · Sale (S): 670 @ $4.15 · +10 moreEDGAR
2024-05-014UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO — 10% ownerSale (S): 6,680 @ $4.92 · Sale (S): 274 @ $4.93 · Sale (S): 100 @ $4.94 · Sale (S): 3,231 @ $5 · Sale (S): 13 @ $5.00 · Sale (S): 448 @ $5.03 · +18 moreEDGAR
2024-04-104/AAmbros Reinhard J. — DirectorGrant/award (A): 2,725 (derivative) @ $0EDGAR
2024-04-104/AVON RICKENBACH JOSEF H — DirectorGrant/award (A): 2,725 (derivative) @ $0EDGAR
2024-03-064WINDSOR JAMES BRIAN — President and COOOption exercise (M): 2,000 · Option exercise (M): 2 (derivative)EDGAR
2024-03-014Ambros Reinhard J. — DirectorGrant/award (A): 2,725 (derivative) @ $0EDGAR
2024-03-014VON RICKENBACH JOSEF H — DirectorGrant/award (A): 2,725 (derivative) @ $0EDGAR
2023-12-184WINDSOR JAMES BRIAN — President and COOPurchase (P): 225 @ $3.37EDGAR
2023-11-214WINDSOR JAMES BRIAN — President and COOPurchase (P): 5,076 @ $1.97EDGAR
2023-11-024Fairey William — DirectorGrant/award (A): 5,450 (derivative) @ $0EDGAR
2023-11-024Musso Alan A — DirectorGrant/award (A): 5,450 (derivative) @ $0EDGAR
2022-06-174Morrison Jodie Pope — DirectorGrant/award (A): 54,500 (derivative) @ $0EDGAR
2022-06-174Ambros Reinhard J. — DirectorGrant/award (A): 54,500 (derivative) @ $0EDGAR
2022-06-174Bailey Jeffrey Allen — DirectorGrant/award (A): 54,500 (derivative) @ $0EDGAR
2022-06-174Sigal Nolan Howard — DirectorGrant/award (A): 54,500 (derivative) @ $0EDGAR
2022-06-174MCKEE WILLIAM — DirectorGrant/award (A): 54,500 (derivative) @ $0EDGAR
2022-06-174VON RICKENBACH JOSEF H — DirectorGrant/award (A): 54,500 (derivative) @ $0EDGAR
2022-03-304/AAivado Manuel — See Remarks, DirectorGrant/award (A): 1,133,000 (derivative) @ $0EDGAR
2022-03-304/AVukovic Vojo — Chief Medical OfficerGrant/award (A): 150,000 (derivative) @ $0EDGAR
2022-03-304/AWanstall Rick — See RemarksGrant/award (A): 393,000 (derivative) @ $0EDGAR
2022-03-304/AAnnis Allen — SVP, ResearchGrant/award (A): 313,000 (derivative) @ $0EDGAR
2022-03-244Wanstall Rick — See RemarksGrant/award (A): 393,000 (derivative) @ $0EDGAR
2022-03-244Annis Allen — SVP, ResearchGrant/award (A): 313,000 (derivative) @ $0EDGAR
2022-03-244Aivado Manuel — See Remarks, DirectorGrant/award (A): 1,133,000 (derivative) @ $0EDGAR
2022-03-244Vukovic Vojo — Chief Medical OfficerGrant/award (A): 150,000 (derivative) @ $0EDGAR
2021-06-174Bailey Jeffrey Allen — DirectorGrant/award (A): 96,000 (derivative) @ $0EDGAR
2021-06-174Aivado Manuel — See Remarks, DirectorGrant/award (A): 2,440,000 (derivative) @ $0EDGAR
2021-06-174Morrison Jodie Pope — DirectorGrant/award (A): 96,000 (derivative) @ $0EDGAR
2021-06-174Ambros Reinhard J. — DirectorGrant/award (A): 96,000 (derivative) @ $0EDGAR
2021-06-174Wanstall Rick — See RemarksGrant/award (A): 600,000 (derivative) @ $0EDGAR
2021-06-174Vukovic Vojo — Chief Medical OfficerGrant/award (A): 400,000 (derivative) @ $0EDGAR
2021-06-174Annis Allen — SVP, ResearchGrant/award (A): 474,000 (derivative) @ $0EDGAR
2021-06-174Sigal Nolan Howard — DirectorGrant/award (A): 96,000 (derivative) @ $0EDGAR
2021-06-174MCKEE WILLIAM — DirectorGrant/award (A): 96,000 (derivative) @ $0EDGAR
2021-06-174VON RICKENBACH JOSEF H — DirectorGrant/award (A): 96,000 (derivative) @ $0EDGAR

Recent 8-K events — Aileron Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-168-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-048-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-278-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2026-07-218-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-048-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-028-K1.01 — Entry into a Material Definitive Agreement
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-198-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-01-168-K1.01 — Entry into a Material Definitive Agreement
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
2025-12-118-K1.02 — Termination of a Material Definitive AgreementEDGAR
2025-11-038-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ALRN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs